STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump

This is a multi‐center, prospective, randomized, double‐blind, placebo‐controlled,non‐inferiority clinical investigation designed to evaluate two different antithromboticregimens in advanced heart failure patients treated with the CH‐VAD pump. The clinicalinvestigation will be conducted at up to 30 centers in China. Eligible study participantswill be randomized between postoperative day 2 and day 7 in a 1:1 ratio to receive eithervitamin K antagonist with aspirin (Aspirin group) or vitamin K antagonist with placebo(Placebo group). Scheduled visits and assessments will be conducted at 1, 3, 6, 9, and 12months post‐implantation.